0000000000134256

AUTHOR

Corrado Lodigiani

0000-0002-9152-9385

showing 8 related works from this author

Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

2019

MalePediatricsmedicine.medical_specialtyhaemophiliacoagulation factors030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineAcquired haemophiliaHumansMedicinecoagulation factorProspective StudiesRegistriesProspective cohort studyActivated prothrombin complex concentrateRetrospective Studiesbleeding disorders; coagulation factors; factor VIII; haemophilia; Blood Coagulation Factors; Female; Hemophilia A; Humans; Italy; Male; Prospective Studies; Retrospective Studies; Registriesbleeding disordersbleeding disorderbusiness.industryRetrospective cohort studyHematologymedicine.diseaseBlood Coagulation FactorsItalyfactor VIIIFemalebusiness030215 immunologyBritish Journal of Haematology
researchProduct

Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients

2020

2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologybusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)10031 Clinic for AngiologyC-reactive protein2720 Hematology610 Medicine & healthHematologymedicine.diseasePneumoniaInternal medicineD-dimerbiology.proteinRetrospective analysisMedicinebusinessLetter to the EditorThrombosis and Haemostasis
researchProduct

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy

2020

Background Few data are available on the rate and characteristics of thromboembolic complications in hospitalized patients with COVID-19. Methods We studied consecutive symptomatic patients with laboratory-proven COVID-19 admitted to a university hospital in Milan, Italy (13.02.2020–10.04.2020). The primary outcome was any thromboembolic complication, including venous thromboembolism (VTE), ischemic stroke, and acute coronary syndrome (ACS)/myocardial infarction (MI). Secondary outcome was overt disseminated intravascular coagulation (DIC). Results We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]). Thromboprophylaxis was used in 100% of ICU patients…

MaleComorbidity030204 cardiovascular system & hematologyBrain Ischemia0302 clinical medicineHospitals UrbanPatient AdmissionRisk FactorsPulmonary angiographyAmbulatory CareThrombophiliaCardiovascular complicationsMyocardial infarctionHospital MortalityAged 80 and overHematologyMiddle AgedPulmonary embolismItaly030220 oncology & carcinogenesisAmbulatoryFemaleCoronavirus InfectionsVenous thromboembolismmedicine.medical_specialtyAcute coronary syndromeCritical CarePneumonia ViralArterial Occlusive DiseasesDisseminated intravascular coagulationThrombophiliaArticle03 medical and health sciencesInternal medicineIntensive caremedicineHumansAcute Coronary SyndromeMortalityHospitals TeachingPandemicsAgedRetrospective Studiesbusiness.industryCoronary ThrombosisAnticoagulantsCOVID-19Retrospective cohort studyLength of Staymedicine.diseaseSARS-CoV2businessPulmonary EmbolismThrombosis Research
researchProduct

Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study

2017

Essentials Isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer. No study has specifically evaluated the long-term clinical course of cancer-associated IDDVT. Patients with cancer-associated IDDVT are at very high risk of symptomatic recurrence and death. We observed low rates of major bleeding during anticoagulation. SummaryBackground Although isolated distal deep vein thrombosis (IDDVT) is frequently associated with cancer, no study has specifically evaluated the long-term clinical course of IDDVT in this setting. Aim To provide data on the rate of recurrent venous thromboembolism (VTE), major bleeding events and death in IDDVT patients with active cancer. Pat…

Malemedicine.medical_specialtydistal deep vein thrombosis; mortality; neoplasm; observational study; venous thromboembolism; HematologyTime FactorsDeep veinHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsNeoplasmsInternal medicinemedicineHumans030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesVenous ThrombosisHematologybusiness.industryIncidenceClinical courseAnticoagulantsCancerdistal deep vein thrombosiVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasemortalityThrombosisSurgeryTreatment Outcomemedicine.anatomical_structureItalyobservational studyFemaledistal deep vein thrombosisPulmonary EmbolismbusinessVenous thromboembolismneoplasmDistal deep vein thrombosis; Mortality; Neoplasm; Observational study; Venous thromboembolism; Hematologymedicine.drugCohort studyJournal of Thrombosis and Haemostasis
researchProduct

Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

2018

After acute proximal deep vein thrombosis (DVT) the thrombotic mass decreases, especially during the first months of anticoagulation. The persistence of residual vein obstruction (RVO) may predict future recurrence in patients with cancer-associated DVT. We aimed to evaluate the proportion of patients with RVO after an episode of cancer associated isolated distal DVT (IDDVT), to identify variables associated with RVO, and to provide initial evidence of its association with recurrent VTE. We performed a post-hoc analysis of a multicenter cohort study of patients with isolated cancer-associated acute IDDVT. We included patients who underwent a control ultrasonography at the end of the anticoa…

AdultMalemedicine.medical_specialtymedicine.drug_classDeep vein030204 cardiovascular system & hematologyCompression ultrasound; Distal deep vein thrombosis; Recurrence; Residual vein obstruction; Venous thromboembolism; Hematology; Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicineRecurrenceRisk FactorsInternal medicineNeoplasmsmedicineHumansIn patientDistal deep vein thrombosiAgedUltrasonographyVenous ThrombosisHematologybusiness.industryRisk FactorAnticoagulantAnticoagulantCancerAnticoagulantsHematologyVenous ThromboembolismCompression ultrasoundMiddle Agedmedicine.diseaseThrombosisSurgeryDiscontinuationmedicine.anatomical_structureDistal deep vein thrombosis030220 oncology & carcinogenesisResidual vein obstructionAcute DiseaseNeoplasmFemalebusinessCardiology and Cardiovascular MedicineHumanCohort studyJournal of thrombosis and thrombolysis
researchProduct

OC-01 - Clinical history of cancer patients with isolated distal deep vein thrombosis: a multicenter cohort study

2016

Introduction Isolated distal deep vein thrombosis (IDDVT) accounts for one-fourth to one-half of all deep vein thrombosis (DVT) of the leg. Patients with IDDVT are frequently treated for a shorter period of time compared to patients with proximal DVT and/or pulmonary embolism (PE) due to a perceived lower risk of recurrence. About 10-20% of patients with venous thromboembolic events (VTEs) have concomitant cancer. Guidelines recommend long-term anticoagulant treatment in this group of patients due to their high risk of VTE recurrence. Unfortunately, information on the clinical history of IDDVT patients is limited and, to date, no study has evaluated the long-term risk of VTE recurrence in I…

medicine.medical_specialtymedicine.drug_classDeep veinPopulationLow molecular weight heparin030204 cardiovascular system & hematologyLower riskGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicinecancerVeineducationThrombosis history; distal deep vein thrombosis;cancerThrombosis historyeducation.field_of_studybusiness.industrydistal deep vein thrombosiHematologymedicine.diseaseThrombosisPulmonary embolismSurgeryVenous thrombosismedicine.anatomical_structure030220 oncology & carcinogenesisbusinessThrombosis Research
researchProduct

Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients

2021

Background: Hemostatic abnormalities have been described in COVID-19, and pulmonary microthrombosis was consistently found at autopsy with concomitant severe lung damage. Methods: This is a retrospective observational cross-sectional study including consecutive patients with COVID-19 pneumonia who underwent unenhanced chest CT upon admittance at the emergency room (ER) in one large academic hospital. QCT was used for the calculation of compromised lung volume (%CL). Clinical data were retrieved from patients’ files. Laboratory data were obtained upon presentation at the ER. Aim: The aim of this study was to evaluate the correlation between hemostatic abnormalities and lung involvement in pa…

medicine.medical_specialtySARS-CoV-2 pneumonia610 Medicine & health2700 General Medicine030204 cardiovascular system & hematologyLung injuryGastroenterologyArticlelung volume measurements03 medical and health sciences0302 clinical medicineInternal medicineD-dimerMedicineLung volumesCOVIDLungbusiness.industry10031 Clinic for AngiologyRCOVID-19General MedicineOdds ratiomedicine.diseasePneumoniamedicine.anatomical_structure030220 oncology & carcinogenesisHemostasisConcomitantD-dimerhemostasisMedicinebusiness
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct